Drug Approval | October 26, 2022
Zydus receives final approval from USFDA for Micafungin for Injection
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
CGHS would give robust coverage to pensioners and with new innovations and practices
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Subscribe To Our Newsletter & Stay Updated
